Diffuse large B-cell lymphoma trials in Italy

In Italy 34 Also abroad 346

34 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Where
Meldola, Milan, Modena, Monza, Naples, Novara, Pavia, Perugia, Ravenna, Roma, Turin, Udine, Varese
Age
18 years and over
People
904 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00
Phase 1Taking people
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Where
Bologna, Milan
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00
Phase 2/3Taking people
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Where
Naples, Rozzano
Age
18 years and over
People
290 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00
Phase 1Taking people
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Where
Candiolo, Milan
Age
18 years and over
People
140 worldwide
Run by
Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659
Phase 2Taking people
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Where
Alexandria, Brescia, Meldola, Milan, Naples, Palermo, Reggio Emilia, Rozzano
Age
18 years and over
People
594 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06890884 · EU 2024-515526-89-00
Phase 1Not yet taking people in Italy
Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Where
Padova, Verona
Age
18 years to 99 years
People
14
Run by
Istituto Oncologico Veneto IRCCS
See details and how to joinNCT07906080 · EU 2026-525494-39-00
Phase 1Taking people
A Study of ARC-02 in B-cell NHL
Where
Aviano, Bergamo, Bologna, Rozzano
Age
18 years and over
People
140 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Milan, Rome, Turin
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 3Taking people
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Where
Ancona, Brescia, Candiolo, Milan, Monza, Novara, Palermo, Ravenna, Rionero In Vulture, Rome
Age
18 years and over
People
1,046 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00
Phase 2Taking people
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Where
Brescia, Meldola, Milan, Naples, Rozzano
Age
18 years and over
People
130 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00
Phase 1Taking people
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Where
Bologna, Milan, Rome, Verona
Age
18 years and over
People
280 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07195916 · EU 2025-523130-11-00
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Bologna, Milan, Roma, Verona
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
No phaseTaking people
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
Where
Ancona, Aviano, Bari, Barletta, Belluno, Bolzano, Brescia, Brindisi, Caltanissetta, Catania, Como, Florence, Lecce, Legnano, Messina, Milan, Modena, Novara, Padova, Pagani, Palermo, Pescara, Piacenza, Pisa, Potenza, Reggio Emilia, Rimini, Roma, Rozzano, Sassari, Sassuolo, Torino, Treviso
Age
18 years to 50 years
People
552
Run by
Fondazione Italiana Linfomi - ETS
See details and how to joinNCT05934084
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Bologna, Milan, Rome, Rozzano
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 2Taking people
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Where
Bologna, Milan, Naples
Age
18 years and over
People
120 worldwide
Run by
Universität Münster
See details and how to joinNCT07197307 · EU 2023-509861-19-01
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Bologna, Brescia, Milan, Rome
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
No phaseNot yet taking people in Italy
Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach
Where
Pavia
Age
18 years and over
People
100 worldwide
Run by
International Extranodal Lymphoma Study Group (IELSG)
See details and how to joinNCT07147751
No phaseNot yet taking people in Italy
Neurocognitive Assessment in Long-Term Survivors of Lymphoma
Where
Ancona, Aviano, Bari, Legnano, Milan, Palermo
Age
25 years to 55 years
People
100
Run by
Fondazione Italiana Linfomi - ETS
See details and how to joinNCT07652476
Phase 2Taking people
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Where
Turin
Age
18 years to 70 years
People
213 worldwide
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00
No phaseTaking people
Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma
Where
Reggio Emilia
Age
18 years and over
People
50
Run by
Azienda USL Reggio Emilia - IRCCS
See details and how to joinNCT06822829
No phaseTaking people
Bio-CAR-T BS Study
Where
Brescia
Age
18 years to 70 years
People
45
Run by
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
See details and how to joinNCT05366569
No phaseNot yet taking people in Italy
Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
Where
Ancona, Avellino, Aviano, Bari, Brescia, Cagliari, Florence, Milan, Monza, Padova, Palermo, Parma, Piacenza, Prato, Ravenna, Reggio Emilia, Roma, Siena, Teramo, Torino, Udine, Verona
Age
70 years and over
People
170
Run by
Fondazione Italiana Linfomi - ETS
See details and how to joinNCT07476105
No phaseNot yet taking people in Italy
Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy
Where
Alessandria, Ancona, Brescia, Palermo, Reggio Calabria, Roma, Taranto, Udine
Age
18 years and over
People
100
Run by
Fondazione Italiana Linfomi - ETS
See details and how to joinNCT07463781
No phaseTaking people
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Where
Bari, Milan, Naples, Palermo, Rome, Turin
Age
18 years and over
People
700 worldwide
Run by
AbbVie
See details and how to joinNCT06830759
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
Alexandria, Milan, Turin, Verona
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00